Biocompatible materials

• US 20050053642A1
• Filed: 08/23/2001
• Published: 03/10/2005
• Est. Priority Date: 08/23/2000
• Status: Abandoned Application

• Current Assignee: Biosurf APS
• Original Assignee: Biosurf APS
• Inventors: Thom, Volkmar, Jonsson, Gunnar, Altankov, George, Jankova, Katja, Ulbricht, Mathias
• Application Number:
  US10/362,677
• Publication Number:
  US 20050053642A1
• Time in Patent Office: Days
• US Class Current: 424/443
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: B82Y 30/00 Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention teaches a novel approach of creating biocmpatible surfaces, said surfaces being capable of functionally interact with biological material. SAid biocompatible surfaces comrise at least two comonents, such as a hydrophobic substratum and a macromolecule of hydrophilic nature, which, in a cooperativity, form together the novel biocoompatible surfaces. The novel approach is ased on contacting said hydrophobic substratum with a laterally patterned monomolecular layer of said hydrophilic and flexible macromolecules, exhibiting a pronounced excluded volume. The htus formed two component surface is, in respect to polarity and morphology, a molecularly heterogeneous surface. Structural features of said macromolecular monolayer (as e.g. the layer thickness or its lateral density) are determined by: i) the structural features of the layer forming macromolecules (as e.g. their MW or their molecular architecture) and ii) the method of creating said monomolecular layer (as e.g. by physi- or chemisorbing, or by chemically binding said macromolecules). The structural features of the layer forming macromolecules(s) is in turn determined by synthesis. AMount and conformation and thus also biological activity of biological material (as e.g. polypeptides) which contact the novel biocompatible surface, is determined and maintained by the cooperative action of the underlying hydrophobic substratum and the macromolecular layer. In this way it becomes possible to maintain and control biological interactions between said contacted polypeptides and other biological compounds as e.g. cells, antibodies and the like. Consequently, the present invention aims to reduce and/or eliminate the deactivation and/or denaturation associated with the contacting of polypeptides and/or other biological material to a hydrophobic substratum surface.

Claims

1. Biocompatible material comprising a substratum contacted by at least one macromolecule,

said material having a first advancing contact angle a,

said substratum having a second advancing contact angle b₀ when not contacted by a macromolecule, and another second advancing contact angle b_sat, when said substratum is saturated by said macromolecules,

wherein said advancing contact angles are measured using water and air saturated by water vapour,

wherein b_sat essentially does not change when the substratum is contacted by further macromolecules by means of a chemical bond,

wherein the relation between said advancing contact angles is as defined by the ratio R,

R=(b₀−

a)/(b₀−

b_sat)

and wherein the numerical value of R is in the interval from 0 to less than 0.4.

2. Material according to claim 1, wherein said substratum is selected from the group consisting of poly(lactide) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes.

3. Material according to claim 1, wherein said substratum is selected from the group consisting of polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, teflon, and nylon.

4. Material according to claim 1, wherein said substratum is selected from the group consisting of homo- and copolymers of linear low density polyethylene (LLDPE), Low density polyethylene (LDPE), High density polyethylene (HDPE), Ethylene/vinylacetate (EVA), Ethylene-methyl-acrylate (EMA), Ethylene-acrylic-acid (EAA), Ethylene-butyl-acrylate (EBA), Ethylene-ethyl-acrylate (EEA), Polypropylene (PP), Ethylene-propylene copolymer (EPM), and Ethylene-propylene-diene terpolymer (EPDM).

5. Material according to claim 1, wherein said substratum is selected from the group consisting of polyethylene (PE), high density polyethylene (HDPE), low density polyethylene (LDPE), polypropylene (PP) and poly(4-methyl-1-pentene) (PMP).

6. Material according to claim 1, wherein said substratum comprises or essentially consists of or consists of a polycarbonate, or a derivative thereof.

7. Material according to claim 1, wherein said substratum comprises or essentially consists of or consists of a polystyrene, or a derivative thereof.

8. Material according to claim 1, wherein said substratum comprises a hydrophobic polymer.

9. Material according to claim 1, wherein said substratum has an advancing contact angle of more than 90 degrees.

10. Material according to claim 1, wherein said substratum is pretreated or modified, wherein said pretreatment or modification results in an increased wettability of the substratum.

11. Material according to claim 10 wherein said pretreated or modified substratum is the result of said substratum being contacted by and/or operably linked to a charged group or a hydrophilic compound.

12. Material according to claim 1, wherein said substratum is subjected to a pretreatment comprising corona treatment and resulting in an increased wettability of said substratum.

13. Material according to claim 1, wherein said substratum is subjected to a pretreatment comprising plasma treatment and resulting in an increased wettability of said substratum.

14. Material according to claim 1, wherein the substratum is further contacted by a plurality of soluble substances capable of forming a self-assembled monolayer comprising at least one macromolecule.

15. Material according to claim 14, wherein said soluble substances are n-alkane chains preferably containing from 8 to 24 carbons.

16. Material according to claim 1, wherein said macromolecule comprises an amphiphilic polymer.

17. Material according to claim 1, wherein said first contact angle is in the range of from 50 degrees to 140 degrees.

18. Material according to claim 1, wherein said first contact angle is in the range of from 60 degrees to 125 degrees.

19. Material according to claim 1, wherein said first contact angle is in the range of from 70 degrees to 120 degrees.

20. Material according to claim 1, wherein said first contact angle is in the range of from 75 degrees to 110 degrees.

21. Material according to claim 1, wherein said first contact angle is in the range of from 80 degrees to 100 degrees.

22. Material according to claim 1, wherein said ratio is less than 0.30.

23. Material according to claim 1, wherein said ratio is less than 0.28.

24. Material according to claim 1, wherein said ratio is less than 0.26.

25. Material according to claim 1, wherein said ratio is less than 0.24.

26. Material according to claim 1, wherein said ratio is less than 0.22.

27. Material according to claim 1, wherein said ratio is less than 0.20.

28. Material according to claim 1, wherein said ratio is less than 0.18.

29. Material according to claim 1, wherein said ratio is less than 0.16.

30. Material according to claim 1, wherein said ratio is less than 0.14.

31. Material according to claim 1, wherein said ratio is less than 0.12.

32. Material according to claim 1, wherein said ratio is less than 0.10.

33. Material according to claim 1, wherein said material, when contacted by a first determinant comprising a compound selected from the group consisting of a polypeptide, or part thereof, a nucleic acid moiety, a carbohydrate moiety, and a lipid moiety, including any combination thereof, is capable of maintaining said compound in a biologically active form.

34. Material according to claim 33 wherein said compound is a polypeptide or part thereof.

35. Material according to claim 33 further comprising said first determinant comprising said compound, wherein said first determinant is maintained in a biologically active form when contacted by said substratum and/or said macromolecule.

36. Material according to claim 35 wherein said biologically active form is essentially a biologically active conformation.

37. Material according to claim 33 wherein said biologically active form or conformation is maintained and/or improved and/or stabilized by means of the cooperativity of said substratum and said macromolecule.

38. Material according to claim 33 wherein said biologically active form or confirmation is maintained and/or improved and/or stabilized when contacted by said substratum and said macromolecule.

39. Material according to claim 1, wherein said material is biocompatible.

40. Material according to claim 1, wherein the weight increase per area unit arising from the part of the macromolecule essentially consisting of PEG or poly(ethylene oxide) (PEO) is less than 2.0×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

41. Material according to claim 40, wherein said difference is less than 1.6×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

42. Material according to claim 40, wherein said difference is less than 1.4×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

43. Material according to claim 40, wherein said difference is less than 1.2×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

44. Material according to claim 40, wherein said difference is less than 1.0×

10<sup>−

22</sup> grams (g) per square nanometer (nm²)

45. Material according to claim 40, wherein said difference is less than 0.8×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

46. Material according to claim 40, wherein said difference is less than 0.5×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

47. Material according to claim 40, wherein said difference is less than 0.3×

10<sup>−

22</sup> grams (g) per square nanometer (nm²).

48. Material according to claim 1 wherein each macromolecule is associated with an excluded volume.

49. Material according to claim 48, wherein said substratum is at least substantially flexible.

50. Material according to claim 48, wherein said substratum is a film.

51. Material according to claim 48, wherein said substratum is essentially rigid or at least substantially non-flexible.

52. Material according to claim 51, wherein said substratum comprises a crystalline structure capable of supporting a self-assembled monolayer such as gold, silicon oxide, and similar crystalline structures and/or structures that are smooth on a nanometer scale.

53. Material according to claim 1, wherein said macromolecule has a MW of more than 400 Da.

54. Material according to claim 53, wherein said macromolecule has a MW of more than 1,000 Da.

55. Material according to claim 53, wherein said macromolecule has a MW of more than 2,000 Da.

56. Material according to claim 53, wherein said macromolecule has a MW of more than 5,000 Da.

57. Material according to claim 53, wherein said macromolecule has a MW of more than 10,000 Da.

58. Material according to claim 53, wherein said macromolecule has a MW of more than 50,000 Da.

59. Material according to claim 53, wherein said macromolecule has a MW of more than 100,000 Da.

60. Material according to claim 1, wherein said macromolecule is a conjugate comprising a head group, a guiding group, a linker group, a polymer chain or a main body, and a functional end group.

61. Material according to claim 1, wherein said macromolecule is a conjugate comprising a head group, a linker group, a polymer chain or a main body, and a functional end group.

62. Material according to claim 1, wherein said macromolecule is a conjugate comprising a head group, a polymer chain or a main body, and a functional end group.

63. Material according to claim 60, wherein said head group is capable of forming a chemical bond.

64. Material according to claim 60, wherein said head group is capable of adsorbing to the substratum.

65. Material according to claim 60, wherein said head group is capable of forming an ionic bond.

66. Material according to claim 60, wherein said head group may be entangled into or with the substratum.

67. Material according to claim 60, wherein said head group is capable of forming a self-assembled monolayer.

68. Material according to claim 60, wherein said guiding group is a bifunctional group comprising an aliphatic, linear or weakly branched group.

69. Material according to claim 61, wherein said linker group is capable of being enzymatically or chemically hydrolyzed.

70. Material according to claim 60, wherein said linker group is hydrolytically unstable and capable of being cleaved.

71. Material according to claim 60, wherein said linker group is essentially stable against cleavage under practical circumstances.

72. Material according to claim 60, wherein said polymer chain or main body is hydrophilic, uncoiling in an aqueous environment and exhibiting an excluded volume.

73. Material according to claim 60, wherein said functional end group is capable of linking permanently or reversibly other biological or synthetic molecules or materials.

74. Material according to claim 33, wherein said first determinant comprises a biologically active compound comprising a polypeptide, or a part thereof, a nucleic acid moiety, a carbohydrate moiety, and a lipid moiety, or any combination thereof.

75. Material according to claim 74, wherein said biologically active compound comprises a polypeptide.

76. Material according to claim 74, wherein said biologically active compound is a membrane associated and/or extracellular matrix polypeptide natively produced by a microbial cell, a plant cell or a mammalian cell.

77. Material according to claim 74 wherein said biologically active compound is selected from the group consisting of a polypeptide, an antibody, a polyclonal antibody, a monoclonal antibody, an immunogenic determinant, an antigenic determinant, a receptor, a receptor binding protein, an interleukine, a cytokine, a cellular differentiation factor, a cellular growth factor, and an antagonist to a receptor.

78. Material according to claim 74, wherein said biologically active compound is a synthetic polypeptide, or part thereof, capable of contacting said substratum and/or said macromolecule.

79. Material according to claim 74, wherein said biologically active compound is a synthetic polypeptide, or part thereof, capable of contacting said substratum and said macromolecule.

80. Material according to claim 74, wherein said biologically active compound is an adhesion polypeptide, preferably fibronectin or vitronectin.

81. Material according to claim 33, wherein said biologically active compound results in an improved contact between said material and a biological entity, such as a biological cell or a virus, or part thereof, including a polypeptide, or a part thereof, a nucleic acid moiety, a carbohydrate moiety, and a lipid moiety, or any combination thereof.

82. Material according to claim 1, said material further comprising a second determinant.

83. Material according to claim 82, wherein said second determinant comprises a biological entity, such as a biological cell or a virus, or part thereof, including a polypeptide, or a part thereof, a nucleic acid moiety, a carbohydrate moiety, and a lipid moiety, or any combination thereof.

84. Material according to claim 82, wherein said biological entity is selected from the group consisting of a polypeptide, an antibody, a polyclonal antibody, a monoclonal antibody, an immunogenic determinant, an antigenic determinant, a receptor, a receptor binding protein, an interleukine, a cytokine, a differentiation factor, a growth factor, and an antagonist to the receptor.

85. Material according to claim 83, wherein said biological cell, or part thereof, is selected from the group consisting of a mammalian cell, a plant cell, and a microbial cell.

86. Material according to claim 85 wherein said biological cell is a mammalian cell.

87. Material according to claim 83, wherein said virus, or part thereof, is selected from a mammalian virus, a plant virus, and a microbial virus.

88. Material according to claim 87 wherein said virus is a mammalian virus.

89. Material according to claim 1, wherein said substratum is porous.

90. Material according to claim 89, wherein the flux of water through said material is substantially unchanged as compared to the flux of water through said porous substratum.

91. Material according to claim 1, wherein said substratum is non-porous and/or substantially non-penetrable to water.

101. Composition comprising the material according to claim 1 and a physiologically acceptable carrier.

102. Pharmaceutical composition comprising the material according to claim 1 and a pharmaceutically active ingredient and optionally a pharmaceutically active carrier.

115. Method of controlling cellular growth and/or cellular proliferation and/or cellular differentiation ex vivo, said method comprising the steps of contacting a cell with the material according to claim 1 and incubating said cell and said material under conditions allowing said cell to grow and/or proliferate and/or differentiate.

116. Method of separating and/or isolating biological material ex vivo, said method comprising the steps of contacting said biological material to be separated and/or isolated with the material according to claim 1 and incubating said biological material and said material under conditions that allow separation and/or isolation.

117. Method of producing a biohybrid organ ex vivo, said method comprising the steps of contacting biohybrid organ cells with the material according to claim 1 and incubating said biohybrid organ cells under conditions allowing the production of said biohybrid organ.

118. Method of therapy carried out on the human or animal body, said method comprising the step of contacting said body with the pharmaceutical composition according to claim 102.

119. Method of surgery carried out on the human or animal body, said method comprising the step of contacting said body with the pharmaceutical composition according to claim 102.

120. Method of diagnosis carried out on the human or animal body, said method comprising the steps of contacting said body with the material according to claim 1 and detecting a signal generated directly or indirectly by said material.

121. Method of controlling cellular growth and/or cellular proliferation and/or cellular differentiation in vivo, said method comprising the steps of contacting a cell with the material according to claim 1 and incubating said cell and said material under conditions allowing said cell to grow and/or proliferate and/or differentiate.

122. Method of separating and/or isolating biological material in vivo, said method comprising the steps of contacting said biological material to be separated and/or isolated with the material according to claim 1 and incubating said biological material and said material under conditions that allow separation and/or isolation.

123. Method of producing a biohybrid organ in vivo, said method comprising the steps of contacting biohybrid organ cells with the material according to claim 1 and incubating said biohybrid organ cells under conditions allowing the production of said biohybrid organ.

124. Method of in vivo delivery of a medicament to a human or animal body in need of said medicament, said method comprising the steps of contacting said body with the pharmaceutical composition according to claim 102 and incubating said body contacted by said pharmaceutical composition under conditions allowing delivery of said medicament.

125. Method for producing the material according to claim 1, said method comprising the steps of i) providing a substratum having a second contact angle, and ii) contacting said substratum with a composition comprising a plurality of macromolecules and iii) providing a biocompatible material comprising a substratum contacted by a plurality of macromolecules,

wherein said material has a first advancing contact angle a,

wherein said substratum has a second advancing contact angle b₀ when not contacted by a macromolecule, and another second advancing contact angle b_sat, when said substratum is saturated by said macromolecules,

wherein said advancing contact angles are measured using water and air saturated by water vapour,

wherein b_sat essentially does not change when the substratum is contacted by further macromolecules by means of a chemical bond,

wherein the relation between said advancing contact angles is as defined by the ratio R,

R=(b₀−

a)/(b₀−

b_sat)

and wherein the numerical value of R is in the interval from 0 to less than 0.4

126. Method according to claim 125, wherein said substratum comprises a hydrophobic polymer.

127. Method according to claim 125, wherein said substratum is pretreated prior to being contacted by said macromolecule.

128. Method according to claim 127, wherein said pretreatment is effective in increasing the wettability of said substratum.

129. Method according to claim 125, wherein said macromolecule comprises a hydrophilic polymer.

130. Method according to claim 125, wherein said macromolecule comprises a latently reactive polymer.

131. Method according to claim 125, wherein macromolecule has a MW of more than 400 Da.

132. Method according to claim 125, wherein said macromolecule comprises a conjugate comprising a cross likable head group, a linker group, a polymer chain, and a functional end group.

133. Method according to claim 132, wherein said cross likable head group is a photo-reactive aryl azide head group.

134. Method according to claim 132, wherein said macromolecule further comprises a modifying agent.

135. Method according to claim 134 wherein said modifying agent is capable of contacting said substratum and forming a self assembled monolayer.

136. Method according to claim 125, said method comprising the further step of contacting said material with a first determinant comprising a biologically active compound.

137. Method according to claim 136, wherein said biologically active compound is selected from the group consisting of a polypeptide, an antibody, a polyclonal antibody, a monoclonal antibody, an immunogenic determinant, an antigenic determinant, a receptor, a receptor binding protein, an interleukine, a cytokine, a cellular differentiation factor, a cellular growth factor, and an antagonist to a receptor.

138. Method according to claim 136, wherein said biologically active compound is a membrane associated and/or extracellular matrix polypeptide natively produced by a microbial cell, a plant cell or a mammalian cell.

139. Method according to claim 136, said method comprising the further step of contacting said material with a second determinant comprising a biological entity.

140. Method according to claim 139, wherein said biological entity comprises a cell or a virus, or a part thereof.

141. Method according to claim 140, wherein said cell, or part thereof, is selected from the group consisting of a mammalian cell, a plant cell, and a microbial cell.

142. Method according to claim 140, wherein said virus, or part thereof, is selected from a mammalian virus, a plant virus, and a microbial virus.

143. Method according to claim 139, wherein said biological entity comprises a polypeptide, or a part thereof, a nucleic acid moiety, a carbohydrate moiety, or a lipid moiety, or any combination thereof.

144. Method according to claim 139, wherein said biological entity is selected from the group consisting of a polypeptide, an antibody, a polyclonal antibody, a monoclonal antibody, an immunogenic determinant, an antigenic determinant, a receptor, a receptor binding protein, an interleukine, a cytokine, a differentiation factor, a growth factor, and an antagonist to the receptor.

92-100. -100. (Cancelled)

103-114. -114. (Cancelled)